A systematic review and meta-analysis suggested that the most occurring immune system adverse events in patients with ankylosing spondylitis treated with IL-17 inhibitors were mucosal and cutaneous infections [53]. The gene discussed is IL17A; the disease is ankylosing spondylitis.